Abivax’s ulcerative colitis Phase 3 trial shows promising efficacy but cancer cases raise safety concerns

Abivax announced that its Phase 3 maintenance trial in ulcerative colitis produced results it called “landmark,” showing the drug’s ability to keep patients in remission.

The company emphasized the drug’s safety profile, which had been a major selling point in earlier studies, reporting low overall adverse‑event rates.

Analysts, however, were unsettled after the trial disclosed several malignancy cases, prompting concerns about the drug’s safety and dampening market enthusiasm.

The mixed outcome suggests the therapy may retain therapeutic promise, but the cancer signals will likely require additional investigation before broader acceptance.